Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Hyperplasia

Hyperplasia

47

Pipeline Programs↗

85

Active Trials↗

52

Companies Involved↗

Hyperplasia is a moderately active landscape with 47 programs across 52 companies. 12 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

68/100

Mech. Concentration

15/100

Completion Rate

85/100

Attrition Rate

10/100

Pipeline

Programs by Phase

Preclinical24

Medroxyprogesterone Acetate

Eli Lilly

Chlorhexidine Varnish

Khyber Medical University Peshawar

Sonazoid™

GE Healthcare

Isoflavones

National Center for Complementary and Integrative Health (NCCIH)

Alcohol

Astellas

Phase 13

Ad-116a

Addpharma Inc.

AD-1161

Addpharma Inc.

Alpha Receptor Antagonist

Yifeng Jing

Phase 28

IV Busulfan

Otsuka

Everolimus

Novartis

Semaglutide

Novo Nordisk

Nbip-01435

Neurocrine Biosciences

Acolbifene Hydrochloride

University of Kansas Medical Center

Phase 312

Metformin Hydrochloride

EMD Serono

Megestrol Acetate

Bristol-Myers Squibb

Lorazepam

Bausch Health Americas, Inc.

Letrozole

Novartis

Percocet Pill

University of Manitoba

Approved

No programs

Analysis

Modality Breakdown

93%

Small molecule

42 of 45 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 96% of 47 pipeline programs.

Analysis

Trial Status

288

clinical trials

Completed157 · 55%

Recruiting35 · 12%

Not yet recruiting32 · 11%

Unknown status18 · 6%

Terminated15 · 5%

Active, not recruiting15 · 5%

Other16 · 6%

Clinical Trials

Trial Activity

288 trials

A Randomized Controlled Trial Comparing Efficacy and Cost Effectiveness of Water Vapour Thermal Therapy (Rezum) and Prostatic Urethral Lift (UroLift) in Men With Benign Prostatic Hyperplasia

Recruiting·CChinese University of Hong Kong·Preclinical·NCT06820606·120 enrolled

A Prospective Assessment of the Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong

Recruiting·CChinese University of Hong Kong·N/A·NCT05292235·2,000 enrolled

Comparison of the Learning Curves of Tri-lobar Versus En-bloc Holmium Laser Enucleation of the Prostate: A Prospective Randomized Clinical Trial

Recruiting·TTanta University·Preclinical·NCT07890103·120 enrolled

A Prospective Randomized Pivotal Trial of the ALPFA Medical Prostate Ablation System Compared With Cystoscopy in Men With Symptomatic Benign Prostatic Hyperplasia

Recruiting·AALPFA Medical·Preclinical·NCT07592299·250 enrolled

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension

Recruiting·CCrinetics Pharmaceuticals Inc.·Preclinical·NCT07159841·153 enrolled

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)

Recruiting·CCrinetics Pharmaceuticals Inc.·Phase 3·NCT07144163·150 enrolled

An Intelligent Wearable Device Based on Electrical Impedance Tomography for Dynamic and Accurate Monitoring of Voiding Function in Patients With Benign Prostatic Hyperplasia

Recruiting·PPeking University Third Hospital·N/A·NCT07357012·40 enrolled

Prospective, Multicentre, Single-Arm Clinical Trial on the Safety and Effectiveness of Transperineal Irreversible Electroporation for the Ablation of Benign Prostatic Hyperplasia

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Preclinical·NCT06867315·99 enrolled

In-Office Transperineal Laser Ablation (TPLA) as a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia (BPH) After Minimally Invasive Surgical Therapies (MIST)

Recruiting·TThe Cleveland Clinic·N/A·NCT07016620·20 enrolled

Tranexamic Acid for Perioperative Haemostatic Optimisation During Transurethral Resection of the Prostate: A Randomized Quadruple-Blind Placebo-Controlled Trial

Recruiting·—·Approved·NCT07460518·80 enrolled

Reduction of Urinary Toxicity of Stereotactic Body Radiation Therapy (SBRT) With Prostatic Urethral Lift (Urolift)

Recruiting·NNorthwell Health·Preclinical·NCT05148156·20 enrolled

A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)

Recruiting·OOlympus Corporation of the Americas·Preclinical·NCT04757116·256 enrolled

A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia

Recruiting·NNeurocrine Switzerland GmbH·Phase 2·NCT07536269·20 enrolled

Natural History Study of Patients With Excess Androgen

Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00250159·3,000 enrolled

Evaluation of Potential Regret Related to Pediatric Surgical and Medical Management of Congenital Adrenal Hyperplasia, and Analysis of Long-term Outcomes.

Recruiting·UUniversity Hospital, Lille·N/A·NCT07781267·40 enrolled

Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)